Package leaflet: Information for the user

Eribulin 0.44 mg/ml solution for injection

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet What Eribulin is and what it is used for

- What you need to know before you use Eribulin
- How to use Eribulin
- Possible side effects
- 5. How to store Eribulin Contents of the pack and other information 6.
- What Eribulin is and what it is used for

Eribulin contains the active substance eribulin and is an anti-

cancer medicine which works by stopping the growth and spread of cancer cells. It is used in adults for locally advanced or metastatic breast

cancer (breast cancer that has spread beyond the original tumour) when at least one other therapy has been tried but has lost its effect. It is also used in adults for advanced or metastatic liposarcoma (a type of cancer that arises from fat tissue) when previous

therapy has been tried but has lost its effect. 2. What you need to know before you use Eribulin

DO NOT use Eribulin if you: • are allergic to eribulin mesilate or any of the other ingredi-

ents of this medicine (listed in section 6) · are breast-feeding

- Warnings and precautions
- Talk to your doctor or nurse before using Eribulin if you

have liver problems

• have a fever or an infection · experience numbness, tingling, prickling sensations, sensi-

- tivity to touch or muscle weakness
- have heart problems
- If any of these affects you, tell your doctor, who may wish to stop
- Children and adolescents Do not give this medicine to children between the ages of 0 to 18

years because it does not work Other medicines and Eribulin

treatment or reduce the dose.

Tell your doctor if you are using, have recently used or might use any other medicines.

Pregnancy, breast-feeding and fertility

Eribulin may cause serious birth defects and should not be used if you are pregnant unless it is thought clearly necessary after

carefully considering all the risks to you and the baby. It may also cause future permanent fertility problems in men if they take it,

and they should discuss this with their doctor before starting treatment. Women of childbearing age should use effective contraception during and up to 3 months after treatment with Eribulin. Eribulin must not be used during breast-feeding because of the possibility of risk to the child. Driving and using machines

Eribulin may cause side effects such as tiredness (very common) and dizziness (common). Do not drive or use machines if you feel

Eribulin contains ethanol (alcohol)

3. How to use Eribulin

tired or dizzy.

noticeable effects.

This medicine contains 40 mg of ethanol in each ml solution for injection. The amount in each ml is equivalent to less than 1 ml beer or 0.4 ml wine.

The small amount of alcohol in this medicine will not have any

Method of administration Eribulin will be given to you by a qualified healthcare professional

as an injection into a vein, over a period of 2 to 5 minutes. The dose you will receive is based on your body surface area

(expressed in squared metres, or m²) which is calculated from

your weight and height. The usual dose of Eribulin is 1.23 mg/m2, but this may be adjusted by your doctor based on your blood test results or other

factors. To ensure that the whole dose of Eribulin is given it is recommended that a saline solution is flushed into the vein after

How often will you be given Eribulin?

Eribulin is usually given on Days 1 and 8 of every 21-day cycle. Your doctor will determine how many cycles of treatment you should receive. Depending on the results of your blood tests, the doctor may need to delay administration of the medicine until the blood tests return to normal. The doctor may also then decide to reduce the dose you are given.

If you have any further questions about the use of this medicine,

Like all medicines, this medicine can cause side effects, although not everybody gets them

If you experience any of the following serious symptoms, stop taking Eribulin and seek medical

Fever, with a racing heartbeat, rapid shallow breathing.

and may result in death.

life-threatening. Other side effects:

attention straight away:

4. Possible side effects

ask your doctor.

cold, pale, clammy or mottled skin and/or confusion. These may be signs of a condition called sepsis - a severe and serious reaction to an infection. Sepsis is uncommon (may

affect up to 1 in 100 people) and can be life-threatening

 Any difficulty breathing, or swelling of your face, mouth, tongue or throat. These could be signs of an uncommon

allergic reaction (may affect up to 1 in 100 people). · Serious skin rashes with blistering of the skin, mouth, eyes and genitals. These may be signs of a condition called Stevens Johnson syndrome/toxic epidermal necrolysis. The frequency of this condition is not known but it can be

Wery common side effects (may affect more than 1 in 10 people) • decrease in the number of white blood cells or red blood cells tiredness or weakness

 loss of appetite, weight loss difficulty breathing, cough · pain in the joints, muscles and back

• fever

headache

Common side effects (may affect up to 1 in 10 people)

• nausea, vomiting, constipation, diarrhoea · numbness, tingling or prickling sensations

- · decrease in the number of platelets (which may result in bruising or taking longer to stop bleeding) • infection with fever, pneumonia, chills
- fast heart rate, flushing
- · vertigo, dizziness • increased production of tears, conjunctivitis (redness and
- · dehydration, dry mouth, cold sores, oral thrush, indigestion, heartburn, abdominal pain or swelling • swelling of soft tissues, pains (in particular chest, back and bone pain), muscle spasm or weakness

soreness of the surface of the eye), nosebleed

- · mouth, respiratory and urinary tract infections, painful urination sore throat, sore or runny nose, flu-like symptoms, throat
- liver function test abnormalities, altered level of sugar, bilirubin, phosphates, potassium, magnesium or calcium in
- inability to sleep, depression, changed sense of taste · rash, itching, nail problems, dry or red skin
- · excessive sweating (including night sweats) · ringing in the ears
- · blood clots in the lungs
- · swelling of the skin and numbness of the hands and feet

the blood

people)

- Uncommon side effects (may affect up to 1 in 100
 - blood clots · abnormal liver function tests (hepatoxicity)
 - · kidney failure, blood or protein in the urine • widespread inflammation of the lungs which may lead to
- · inflammation of the pancreas
- Rare side effects (may affect up to 1 in 1 000 people)

• a serious disorder of blood clotting resulting in the widespread formation of blood clots and internal bleeding

· mouth ulcers

This includes any possible side effects not listed in this leaflet!

Reporting of side effects

You can also report side effects directly via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for 'MHRA Yellow Card' in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5. How to store Eribulin

If you get any side effects, talk to your doctor or pharmacists

Keep this medicine out of the sight and reach of children.

last day of that month.

What Eribulin contains

Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the

This medicine does not require any special storage conditions. If Eribulin is diluted for infusion, the diluted solution should be used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user and would

normally not be longer than 24 hours at 2 to 8 °C unless dilution has taken place in controlled and validated aseptic conditions. If Eribulin as an undiluted solution has been transferred into a

hours, or at 2-8°C for no longer than 96 hours.

syringe, it should be stored at 20-25°C for no longer than 24

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

The active substance is eribulin. Each 2 ml vial contains

The other ingredients are ethanol and water for injections.

with hydrochloric acid (diluted) and sodium hydroxide possibly present in very small amounts.

eribulin mesilate equivalent to 0.88 mg eribulin.

- What Eribulin looks like and contents of the pack Eribulin is a clear, colourless aqueous solution for injection provided in glass vials containing 2 ml of solution. Each carton

contains either 1 or 6 vials.

Not all pack sizes may be marketed. **Marketing Authorisation Holder** STADA.

I inthwaite Huddersfield, HD7 5QH,

Manufacturer

20355 Hamburg, Germany To request a copy of this leaflet in braille, large print or audio please call 01484 848164.

Kaiser-Wilhelm-Str. 89,

AqVida GmbH,

This leaflet was last revised in November 2023